beginner8 min read

Clinical Trial Phases Explained

Reviewed by Blane Jackson, DDS, MBA. Educational guide only. See the editorial policy and disclosures.

If you're new to biotech investing, you've probably seen headlines like 'Company X announces positive Phase 2 results' or 'Phase 3 trial fails.' But what do these phases actually mean? And why do they matter for your portfolio? In this guide, we'll break down the clinical trial process—Phase 1, 2, and 3—in plain English. You'll learn what each phase is designed to test, how long they take, and the odds of success at each stage. We'll also give you concrete tips on how to interpret trial news and what to look for before investing. By the end, you'll be able to read clinical trial headlines with confidence and make smarter investment decisions.

What Are Clinical Trials and Why Do They Matter?

Before a new drug can be sold, it must go through a rigorous testing process to prove it's safe and effective. This process is called clinical development, and it's divided into phases. Each phase has a specific goal and involves a different number of participants. Think of it like a funnel: many drugs enter Phase 1, but only a few make it to market. For investors, understanding these phases is crucial because each phase represents a major catalyst—a potential big jump or drop in the stock price. When a company announces results from a Phase 2 or Phase 3 trial, the market reacts strongly. Knowing what the results mean can help you avoid costly mistakes and spot opportunities.

Key takeaway

Clinical trials are the gatekeepers of drug approval, and each phase is a major milestone that can move a stock significantly.

Example

In 2020, when Moderna announced positive Phase 1 data for its COVID-19 vaccine, the stock surged over 20% in a day. That's the power of trial results.

Phase 1: Safety First

Phase 1 is the first time a drug is tested in humans. The main goal is to assess safety and find the right dose. These trials are small, typically involving 20-80 healthy volunteers (or sometimes patients with the disease if the drug is too toxic for healthy people). Participants are closely monitored for side effects, and researchers gradually increase the dose to find the maximum tolerated dose. Phase 1 trials usually last several months to a year. Success rates are relatively high—about 70% of drugs move on to Phase 2—but that's because the bar is low: the drug just needs to be safe enough to continue testing. For investors, Phase 1 results are often not a huge catalyst unless the drug is a novel platform or the data is exceptionally good. But they can provide an early signal about the drug's potential.

Key takeaway

Phase 1 is about safety, not efficacy. A successful Phase 1 means the drug is safe enough to test further, but it says little about whether it actually works.

Example

In 2021, a small biotech called Cassava Sciences reported Phase 1 results for its Alzheimer's drug, simufilam. The stock soared because the drug showed cognitive improvement in a small group of patients, but later trials were controversial.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

Phase 2: Does It Work?

Phase 2 is where we start to see if the drug actually works. These trials involve a few hundred patients with the disease. The primary goal is to evaluate efficacy—does the drug improve a clinical endpoint, like shrinking a tumor or lowering blood sugar? Phase 2 also continues to monitor safety. These trials are often randomized and placebo-controlled, meaning some patients get the drug and others get a placebo, to compare outcomes. Phase 2 can take anywhere from one to three years. Success rates drop significantly: only about 33% of drugs that enter Phase 2 will make it to Phase 3. For investors, Phase 2 results are a major catalyst. Positive results can send a stock soaring, while negative results can crush it. But beware: Phase 2 results are not definitive. They are often based on surrogate endpoints (like biomarkers) that may not translate to real-world benefits.

Key takeaway

Phase 2 is the first real test of efficacy. Positive results are exciting, but they're not a guarantee of success in larger trials.

Example

In 2022, a biotech called Amylyx reported positive Phase 2 results for its ALS drug, AMX0035. The stock jumped over 100% on the news. The drug was later approved, but the Phase 2 data was not without controversy.

Phase 3: The Big Test

Phase 3 is the final and most rigorous phase before a company can apply for FDA approval. These trials are large, often involving thousands of patients, and are designed to confirm the drug's efficacy and monitor for rare side effects. They are typically randomized, double-blind, and placebo-controlled—the gold standard. Phase 3 trials can last several years and cost hundreds of millions of dollars. Success rates are around 50-60% for drugs that make it to Phase 3, but that's still a coin flip. For investors, Phase 3 results are the biggest catalyst of all. A successful Phase 3 trial can lead to a buyout or a huge stock rally; a failure can wipe out most of the company's value. It's essential to understand the trial design, endpoints, and statistical significance before the results come out.

Key takeaway

Phase 3 is the make-or-break moment. Positive results can lead to approval and blockbuster sales, but failure is common and devastating.

Example

In 2021, Biogen's Alzheimer's drug aducanumab had mixed Phase 3 results, but the FDA approved it anyway, causing controversy. On the other hand, in 2022, a Phase 3 trial for a diabetes drug by a small biotech failed, and the stock dropped 80% overnight.

Success Rates and What They Mean for Investors

Understanding the odds is crucial. According to a 2018 study by the Biotechnology Innovation Organization (BIO), the overall probability of a drug going from Phase 1 to FDA approval is only about 9.6%. That means roughly 1 in 10 drugs that enter clinical trials will eventually make it to market. Here's a breakdown: Phase 1 to Phase 2: ~70% success rate; Phase 2 to Phase 3: ~33% success rate; Phase 3 to approval: ~50-60% success rate. These numbers vary by disease area—cancer drugs have lower success rates, while rare disease drugs have higher ones. For investors, this means that most biotech stocks are risky. Even a drug that looks promising in Phase 2 has a high chance of failing in Phase 3. That's why diversification is key. Don't put all your money into one clinical-stage biotech.

Key takeaway

The odds are stacked against any single drug. Only about 9.6% of drugs that enter Phase 1 eventually get approved, so diversification is essential.

Example

A 2016 study found that the success rate for oncology drugs from Phase 1 to approval was just 5.1%, while for rare diseases it was 25.9%. This shows how much disease area matters.

How to Read Clinical Trial Results as an Investor

When a company announces trial results, you need to look beyond the headline. Here are key things to check: 1) Did the trial meet its primary endpoint? This is the main measure of success. If it missed the primary endpoint, the trial is generally considered a failure, even if secondary endpoints were positive. 2) Was the effect statistically significant? Look for p-values less than 0.05, which means the results are unlikely to be due to chance. 3) How large was the effect? A small effect might not be clinically meaningful or commercially viable. 4) What were the safety issues? Serious side effects can limit the drug's market potential. 5) Who is the patient population? Results in a narrow group may not generalize. Also, consider the trial design: was it randomized, double-blind, placebo-controlled? These are more reliable than open-label or single-arm trials.

Key takeaway

Don't just read the headline—dig into the details: primary endpoint, statistical significance, effect size, safety, and trial design.

Example

In 2023, a company announced 'positive' Phase 2 results, but the stock dropped because the primary endpoint was missed and only a secondary endpoint was met. Investors who read the press release carefully could have avoided the loss.

What Investors Should Expect at Each Phase

Here's a practical guide to what happens to a stock around each phase: Phase 1: Usually a modest catalyst. The stock might move 10-20% on positive data, but the market knows the drug is far from approval. Phase 2: This is where big moves happen. Positive Phase 2 data can double or triple a stock, especially for small caps. Negative data can crush it. Phase 3: The biggest catalyst. Positive results can lead to a buyout or a huge rally, but the stock may have already priced in some success. Negative results are often catastrophic. Also, be aware of the 'sell the news' phenomenon: a stock might rise into the data readout and then fall even on positive results because investors take profits. Timing is everything.

Key takeaway

Expect the biggest stock moves around Phase 2 and Phase 3 data readouts, but be prepared for volatility and 'sell the news' events.

Example

In 2020, a small biotech called Inovio Pharmaceuticals saw its stock soar on positive Phase 1 COVID-19 vaccine data, but it later crashed when the Phase 2 data was underwhelming. Investors who bought the hype lost money.

Key terms

Clinical Trial

A research study that tests a new drug or treatment in people to see if it is safe and effective.

Phase 1 Trial

The first stage of human testing, focused on safety and dosage, usually involving 20-80 healthy volunteers.

Phase 2 Trial

A trial that tests the drug's effectiveness in a few hundred patients, while continuing to monitor safety.

Phase 3 Trial

A large, confirmatory trial involving thousands of patients, designed to prove efficacy and monitor rare side effects.

Primary Endpoint

The main outcome measure that a trial is designed to evaluate, such as tumor shrinkage or survival rate.

Placebo

An inactive substance given to a control group to compare against the drug's effects.

Randomized Controlled Trial

A trial where participants are randomly assigned to receive the drug or a placebo, reducing bias.

Double-Blind

A trial design where neither the participants nor the researchers know who is getting the drug until the trial ends.

Statistical Significance

A measure of whether a result is likely due to chance. A p-value less than 0.05 is typically considered significant.

Surrogate Endpoint

A substitute measure, like a biomarker, that is used in place of a clinical outcome, such as survival.

Next steps

Before investing in a clinical-stage biotech, identify which phase its lead drug is in and understand the success rates for that phase.

When a company announces trial results, read the full press release and look for the primary endpoint, p-value, and safety data.

Diversify your biotech portfolio across multiple companies and phases to reduce the risk of any single trial failure.

Set a watchlist for upcoming Phase 2 and Phase 3 data readouts and decide in advance how you'll react to positive or negative results.

Learn to interpret trial designs: favor randomized, double-blind, placebo-controlled trials over open-label or single-arm studies.

Put this guide to work

Use these free ClinicalInvestor tools to apply what you just learned.

2026 PDUFA Calendar →

Every FDA decision in 2026 with AI investor analysis.

Biotech Catalyst Calendar →

PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.

Trial Translator →

Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.

Biotech Screener →

Filter 600+ biotechs by area, phase, market cap, and runway.

Company Profiles →

Pipelines, bull/bear cases, and catalyst lists for every covered biotech.

Keep learning

How to Read Clinical Trial Data →Biotech Stock Catalysts Guide →PDUFA Dates Explained →Understanding Clinical Trial Endpoints →